The safety and efficacy of anti-diabetic drugs are critical for maximizing the beneficial
impacts of well-controlled blood glucose on the prognosis of individuals with COVID-19 and …

Abstract Coronavirus disease 2019 (COVID-19) is a new pandemic the entire world is facing
since December of 2019. Several risk factors are identified in developing severe disease …

Type 2 diabetes mellitus (T2DM) is associated with both poorer clinical outcomes during the
COVID-19 pandemic and an increased risk of death in such hospitalized patients. While the …

Aim COVID-19 has spread globally with heavy impact on most countries and our therapeutic
strategies in COVID-19 patients with diabetes are still limited. Recently, some new …

Objectives: Pre-existing or new diabetes confers an adverse prognosis in people with Covid-
19. We reviewed the clinical literature on clinical outcomes in metformin-treated subjects …

The current outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐
2) infection has spread across the world. No specific antiviral agents have been adequately …

Background and aims Diabetes is one of the most common comorbidities, and it is
associated with poorer outcomes in patients with coronavirus disease 2019 (COVID-19) …

Aims Metformin exerts anti-inflammatory and immunosuppressive effects. We addressed the
impact of prior metformin use on prognosis in patients with type 2 diabetes hospitalised for …

Metformin was proposed to be a candidate for host-directed therapy for COVID-19. However,
its efficacy remains to be validated. In this study, we compared the outcome of metformin …

Aims To determine the association between metformin use and mortality and ARDS
incidence in patients with COVID-19 and type 2 diabetes. Methods This study was a multi …